A review of microstructural changes occurring during FSW in aluminium alloys and their modelling

Friction stir welding (FSW) process is currently considered as a promising alternative to join aluminium alloys. Indeed, this solid-state welding technique is particularly recommended for the assembly of these materials. Since parts are not heated above their melting temperature, FSW process may prevent solidification defects encountered in joining aluminium alloys and known as limitations to the dissemination of these materials in industries. During the past years, large literature has been devoted to the modelling of microstructural evolution in aluminium alloys during FSW processes and mainly dedicated to the analysis of precipitate evolutions and grain recrystallization mechanisms. Precipitate size distribution models have aroused widespread interest in recent years demonstrating their relevance to follow precipitation process in multicomponent alloys and multiphase systems. Efficient recrystallization models are also available and based on various grain growth mechanisms. In addition, multi-scale coupling strategies have recently emerged considering thermal, mechanical and metallurgical solutions. Consequently, the effect of FSW process parameters on weld properties is now investigated to determine optimized welding strategies regarding microstructure evolution. This research is based on reliable models reported in the literature enhancing the estimation of final weld state and associated properties as an answer to industrial needs. Validations of proposed modelling strategies have been reported based on in-depth analyses of experimental observations. This present work proposes a review of recent models dedicated to microstructural evolutions in aluminium alloys during FSW process. The interest and efficiency of current approaches will be discussed to highlight their limitations. Guidelines will propose new routes toward enhanced modelling strategies for future developments

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron